FDA
-
-
-
-
-
-
-
Coherus presents data on CHS-114 cancer drug at SITC conference
-
-
-
-
-
-
-
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Coherus Completes Divestiture of Ophthalmology Franchise
-
-
-
-
-
-
-
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal
-
-
-
-
-
-
-
Coherus Completes Surface Oncology Acquisition
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) Announces FDA Approves UDENYCA Autoinjector
-
-
-
-
-
-
-
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
-
323,993 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

